TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

TELA Bio, Inc.NASDAQ: TELA

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables dips below year-ago levels

Q2 FY2026 accounts payables of $1.01M (cash outflow) fell 55.9% year over year, behind the +308.6% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 0.2% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -55.9% toward the trailing-twelve-month pace of +308.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.01M-163.7% QoQ
Last fiscal yearDec 2025
$141K-70.7% YoY
LTMJun 2026
$1.17M+308.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.9%——
1 year-70.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
141K USD
Year-over-year change
-70.7%
4-year CAGR
-45.5%

Accounts Payables vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 accounts payables of $1.17M is the 4th largest of the 9 companies compared; the peer median is $283.74K.
  • Its year-over-year change of +308.6% is the 3rd highest of 9, against a peer median of +64.7%.
  • Accounts payables amounts to 1.5% of revenue for TELA, versus a peer median of 6.0%.
TELA Competitors Peer median
Accounts Payables for TELA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$4.9M +28.5%+8.8%1472.1%
EQEquillium, Inc.LTM Mar 2026$1.88M -646.1%——
MDAISpectral AI, Inc.LTM Mar 2026$1.67M +663.8%—10.0%
TELATELA Bio, Inc.LTM Jun 2026$1.17M +308.6%—1.5%
SRTSSensus Healthcare, Inc.LTM Mar 2026$943K -148.8%—4.2%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$764K +6466.7%-36.8%—
CUECue Biopharma, Inc.LTM Mar 2026$458K +239.3%+138.4%1.4%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$109.49K -55.4%+121.5%7.7%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$64K +100.9%—2.8%
Peer median (excluding TELA) $283.74K+64.7%+65.1%6.0%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Depreciation & Amortization535K1.19M808K1.01M1.01M
Deferred Income Tax14K00(144K)230K
Stock-Based Compensation3.66M3.99M5.03M4.36M3.8M
Change in Working Capital(3.47M)(5.76M)(1.67M)(4.87M)1.5M
Accounts Receivables(1.55M)(2.42M)(3.06M)(762K)(110K)
Inventory(5.19M)(6.07M)(2.72M)(2.97M)(503K)
Accounts Payables1.6M(884K)11K482K141K
Other Working Capital1.69M3.62M4.1M(1.62M)1.97M
Other Non-Cash Items2.1M4.14M1.64M(4.12M)4.08M
Operating Cash Flow(30.43M)(40.75M)(40.86M)(41.6M)(28.22M)
Capital Expenditures(627K)(1.87M)(611K)(989K)(448K)
Acquisitions (Net)00001.29M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(1M)12K5.44M0
Investing Cash Flow(627K)(1.87M)(599K)4.45M846K
Debt Repayment010M0014.03M
Common Stock Issued585K34.4M46.34M42.92M11.82M
Common Stock Repurchased0000105K
Dividends Paid00000
Other Financing Activities0(3.55M)(74K)138K(205K)
Financing Cash Flow585K40.85M46.27M43.06M25.75M
Effect of Forex Changes11K(144K)164K28K(217K)
Net Change in Cash(30.46M)(1.91M)4.98M5.94M(1.84M)
Free Cash Flow(31.06M)(42.62M)(41.47M)(42.58M)(28.67M)

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.